Other Mutations: PI3K

NCT05455619: Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer

NCT05455619
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a tumor that expresses the PIK3CA mutation
Exclusions: Patients with inflammatory breast cancer; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients who have received prior PI3K/Akt/mTOR inhibitor (e.g. Piqray/alpelisib, Afinitor/everolimus) or fulvestrant treatment
https://ClinicalTrials.gov/show/NCT05455619

NCT05307705: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have solid tumor with the presence of a PIK3CA H1047R mutation
Exclusions: Patients with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement; Patients with prior exposure to PI3K/AKT/mTOR inhibitor(s) – see trial for details
https://ClinicalTrials.gov/show/NCT05307705

Up ↑